Chordate Medical receives decision to delist its shares from NGM Nordic SME conditional on approval from Nasdaq First North Growth Market

The Board of Directors of Chordate Medical (publ) ("Chordate" or "the company") has received a decision to delist its shares from NGM Nordic SME conditional on Chordate receiving final approval from Nasdaq First North Growth Market. Nordic Growth Market NGM AB ("NGM") has today decided that the last day for trading in the Chordate's shares on Nordic SME shall be 14/2, 2022, provided that trading in the Company's shares can be admitted on Nasdaq First North Growth Market the following trading day.

As previously communicated, The Board believes that a change of trading venue for the company's shares to Nasdaq First North Growth Market will increase the knowledge of the company both in Sweden and internationally, making it easier for industrial investors to become shareholders, and have a positive impact on the company's relationships with partners and potential customers. Overall, a change of trading venue is considered to be positive for Chordate's development and completion of the stated exit strategy. Nasdaq First North Growth Market is Nasdaq's European growth market, with the same legal status as NGM Nordic SME.

Provided that Chordate receives final approval from Nasdaq, the company's share will continue to be traded under the short name CMH with the current ISIN code SE0009495559. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.

Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate's legal advisor.

This disclosure was submitted for publication, through the contact person below, on January 28th, 2022, at 15:20 am CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277

The following documents can be retrieved from beQuoted

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact